MARKET

DYN

DYN

Dyne Therapeutics, Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

28.61
-0.44
-1.51%
After Hours: 28.61 0 0.00% 16:00 01/15 EST
OPEN
28.80
PREV CLOSE
29.05
HIGH
29.80
LOW
27.93
VOLUME
157.93K
TURNOVER
--
52 WEEK HIGH
29.93
52 WEEK LOW
15.60
MARKET CAP
1.19B
P/E (TTM)
-44.3085
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Dyne Therapeutics Myotonic Dystrophy Type 1 Program Achieves Robust RNA Knock Down of Toxic Human Nuclear DMPK in Preclinical Study
- In Vivo Model Developed by Dyne Sets New Standard for Evaluating Pharmacodynamics in DM1 -
GlobeNewswire · 01/10 20:00
Dyne Therapeutics Myotonic Dystrophy Type 1 Program Achieves Robust RNA Knock Down of Toxic Human Nuclear DMPK in Preclinical Study
\- In Vivo Model Developed by Dyne Sets New Standard for Evaluating Pharmacodynamics in DM1 -\- Preclinical Data Further Validate FORCE™ Platform; IND Submissions Planned for DM1, DMD and FSHD Programs Between Q4’21 and Q4’22 -WALTHAM, Mass., Jan. 10, 2021...
GlobeNewswire · 01/10 20:00
Dyne Therapeutics to Present at 39th Annual J.P. Morgan Healthcare Conference
Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that Joshua Brumm, president and chief executive officer, and Romesh Subramanian, Ph.D., chief scientific officer, are scheduled to present at the virtual 39 Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2021 at 10:00 a.m. ET.
GlobeNewswire · 01/05 12:30
Dyne Therapeutics to Present at 39th Annual J.P. Morgan Healthcare Conference
GlobeNewswire · 01/05 12:30
Cerevance Appoints David Lubner to Board of Directors
GlobeNewswire · 12/08/2020 15:17
Cerevance Appoints David Lubner to Board of Directors
Cerevance, a private drug discovery and development company focused on brain diseases, today announced the appointment of David Lubner, a senior finance executive with more than 25 years of experience in the life sciences industry, to Cerevance's Board of Directors.
GlobeNewswire · 12/08/2020 15:17
Dyne Therapeutics to Present at Upcoming Investor Conferences
GlobeNewswire · 11/09/2020 12:30
Dyne Therapeutics Reports Third Quarter 2020 Financial Results and Recent Highlights
\- Successful Financings, including $268 Million Initial Public Offering and $116 Million Series B Expected to Fund Through Proof of Concept Data in Co-lead Programs, Myotonic Dystrophy Type 1 and Duchenne Muscular Dystrophy -WALTHAM, Mass., Nov. 05, 2020 (GLOBE NEWSWIRE) --  Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today reported financial results for the third quarter 2020 and recent business highlights. “We made important progress across the business in the third quarter, including securing significant funding through multiple financings culminating with our IPO, continuing to attract exceptional leaders to Dyne with expertise in muscle and rare diseases, and generating platform-validating preclinical data that is creating momentum for our pipeline,” said Joshua Brumm, president and chief executive officer of Dyne. “We expect we have the cash resources to support our planned IND submissions for our three programs between the fourth quarter of 2021 and the fourth quarter of 2022, and to achieve proof-of-concept data for two of those – our myotonic dystrophy type 1 and Duchenne muscular dystrophy programs. Following this exciting third quarter, Dyne is well positioned to pursue our goal of becoming the world’s leading muscle disease company.”Recent Highlights * On September 21, 2020, Dyne completed its IPO of 14,089,314 shares of its common stock, including the full exercise by the underwriters of their option to purchase 1,837,736 additional shares, at an IPO price of $19.00 per share. Gross proceeds of the offering, before deducting the underwriting discount and commissions and offering expenses, were $267.7 million. * The Company continued to generate preclinical data during the quarter for its myotonic dystrophy type 1 (DM1) program: * The importance of Transferrin 1 receptor (TfR1), which is highly expressed on muscle cells, is foundational to Dyne’s FORCE platform and approach to developing modern oligonucleotide therapeutics for serious muscle diseases. To accelerate its work across its platform and programs, Dyne developed a preclinical model for DM1 which expresses the human TfR1 receptor rather than the murine TfR1 receptor. In a preclinical study utilizing this model, two doses of the FORCE conjugate targeting TfR1 resulted in significant reductions in cytoplasmic wild type DMPK RNA in the tibialis anterior, gastrocnemius, heart and diaphragm muscles. * In a separate study of DM1 patient cells, a single dose of Dyne’s FORCE conjugate reduced nuclear DMPK foci by approximately 40 percent as determined through a fluorescence in situ hybridization analysis. * In August 2020, Dyne completed its Series B preferred stock financing, raising gross proceeds of $115.7 million. * In August 2020, Dyne appointed Susanna High, MBA, as its chief operating officer (COO). Ms. High has more than two decades of experience leading corporate strategy, portfolio management, business planning and operations for biotechnology companies. Prior to joining Dyne, her most recent position was COO of bluebird bio, and previously she held roles of increasing responsibility at Alnylam Pharmaceuticals, including as senior vice president, strategy and business integration. * In July 2020, the Company appointed pediatric neurologist Francesco Muntoni, FRCPCH, FMedSci, to its Scientific Advisory Board. Dr. Muntoni is a global leader in clinical research into neuromuscular disease, with particular expertise in clinical care, clinical trial design and drug development for Duchenne muscular dystrophy. * Romesh Subramanian, Ph.D., chief scientific officer, reviews Dyne’s novel approach to developing modern oligonucleotides for serious muscle diseases at TIDES Europe: Oligonucleotide & Peptide Therapeutics in a presentation that is available on demand for registered attendees at https://informaconnect.com/tides-europe/. Dr. Subramanian will also participate in a panel discussion, “Oligonucleotide Delivery Beyond Liver and Targeted Delivery,” during the virtual conference on Wednesday, November 11, 2020 at 9:45 am ET. Third Quarter 2020 Financial ResultsCash and cash equivalents: Cash and cash equivalents were $379.6 million as of September 30, 2020 compared to $14.6 million as of December 31, 2019.Research and development (R&D) expenses: R&D expenses were $9.7 million for the third quarter 2020 compared to $3.0 million for the third quarter of 2019.General and administrative (G&A) expenses: G&A expenses were $3.8 million during the third quarter of 2020 compared to $0.6 million for the third quarter of 2019.Net loss: Net loss was $13.9 million or $2.01 per common share for the third quarter 2020 compared to $5.9 million, or $2.36 per common share for the third quarter 2019.About Dyne TherapeuticsDyne Therapeutics is building a leading muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases. The Company utilizes its proprietary FORCE™ platform to overcome the current limitations of muscle tissue delivery with modern oligonucleotide therapeutic candidates. Dyne is developing a broad portfolio of therapeutics for muscle diseases, including lead programs in myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD). For more information, please visit www.dyne-tx.com, and follow us on Twitter, LinkedIn and Facebook.Forward-Looking StatementsThis press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this press release, including statements regarding Dyne’s strategy, future operations, prospects, plans, objectives of management, the expected timeline for submitting investigational new drug applications and achieving proof-of-concept data readouts and the sufficiency of its cash resources, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “objective,” “ongoing,” “plan,” “predict,” “project,” “potential,” “should,” or “would,” or the negative of these terms, or other comparable terminology are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Dyne may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including: uncertainties inherent in the identification and development of product candidates, including the conduct of research activities, the initiation and completion of preclinical studies and clinical trials; uncertainties as to the availability and timing of results from preclinical studies; the timing of and Dyne’s ability to submit and obtain regulatory approval for investigational new drug applications; whether results from preclinical studies will be predictive of the results of later preclinical studies and clinical trials; Dyne’s ability to obtain sufficient cash resources to fund the Company’s foreseeable and unforeseeable operating expenses and capital expenditure requirements; the impact of the COVID-19 pandemic on Dyne’s business and operations; as well as the risks and uncertainties identified in Dyne’s filings with the Securities and Exchange Commission (SEC), including the Company’s most recent Form 10-Q and in subsequent filings Dyne may make with the SEC. In addition, the forward-looking statements included in this press release represent Dyne’s views as of the date of this press release. Dyne anticipates that subsequent events and developments will cause its views to change. However, while Dyne may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Dyne’s views as of any date subsequent to the date of this press release.Contact:Dyne Therapeutics Amy Reilly areilly@dyne-tx.com 857-341-1203Dyne Therapeutics, Inc. Condensed Statement of Operations (Unaudited) (in thousands, except share and per share data)             Three Months Ended September 30, Nine Months Ended September 30,    2020   2019   2020   2019  Operating expenses:         Research and development $9,679  $2,982  $23,102  $6,781  General and administrative  3,841   647   6,945       1,575  Total operating expenses   13,520    3,629    30,047    8,356   Loss from operations  (13,520)  (3,629)  (30,047)  (8,356) Other (expense) income  (400)  (2,242)  (741)  (1,100) Net loss $ (13,920) $ (5,871) $ (30,788) $   (9,456) Net loss per share—basic and diluted $(2.01) $   (2.36) $   (7.51) $   (3.94) Weighted-average common shares outstanding used in net loss per share—basic and diluted  6,920,008   2,491,487   4,100,504   2,401,039  Dyne Therapeutics, Inc. Condensed Balance Sheet Data (Unaudited) (in thousands)         September 30, December 31,    2020  2019 Assets     Cash and cash equivalents $379,606 $14,632 Other assets                     1,866                    1,804 Total assets $ 381,472  $ 16,436 Liabilities and Stockholders’ Equity     Liabilities                   14,627                   2,400 Stockholders’ equity                 366,845                  14,036 Total liabilities and stockholders’ equity $ 381,472  $ 16,436
GlobeNewswire · 11/05/2020 12:35
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of DYN. Analyze the recent business situations of Dyne Therapeutics, Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average DYN stock price target is 34.25 with a high estimate of 47.00 and a low estimate of 27.00.
EPS
Institutional Holdings
Institutions: 49
Institutional Holdings: 27.01M
% Owned: 64.87%
Shares Outstanding: 41.63M
TypeInstitutionsShares
Increased
0
0
New
49
27.01M
Decreased
0
0
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.34%
Pharmaceuticals & Medical Research
+0.21%
Key Executives
Chairman/Executive Director/Director
Jason Rhodes
President/Chief Executive Officer/Director
Joshua Brumm
Chief Operating Officer
Susanna High
Chief Scientific Officer
Romesh Subramanian
Vice President - Finance/Primary Contact
Gene Kim
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About DYN
Dyne Therapeutics Inc. is a biotechnology company focused on developing therapeutics for patients with genetically driven diseases. The Company’s FORCE platform therapeutics consists of an oligonucleotide payload that it designs to target the genetic basis of the disease. With its FORCE platform, the Company has the flexibility to deploy different types of oligonucleotide payloads with specific mechanisms of action that modify target functions. Using its FORCE platform, the Company is assembling a portfolio of muscle disease therapeutics, including its lead programs in myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD), and facioscapulohumeral dystrophy (FSHD). Its therapeutics consist of three components: a proprietary Fab, a clinically validated linker and an oligonucleotide payload that it attaches to its Fab using the linker. Its DM1 program is focused on the development of a potentially disease-modifying treatment for DM1.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Dyne Therapeutics Inc stock information, including NASDAQ:DYN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DYN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading DYN stock methods without spending real money on the virtual paper trading platform.